Duchenne Muscular Dystrophy Research: How Blood Biomarkers Are Replacing Muscle Biopsies
Duchenne muscular dystrophy (DMD) represents one of the most devastating genetic disorders affecting children worldwide, and is one of the conditions covered by our genetic disease biospecimen portfolio. This X-linked recessive condition, caused by mutations in the dystrophin gene, leads to progressive muscle degeneration, loss of ambulation typically by age 12, and ultimately respiratory and cardiac failure. For decades, muscle biopsies have been the gold standard for diagnosing DMD, but a paradigm shift is underway.
Recent breakthroughs in biomarker science have revealed that simple blood samples can provide remarkably detailed insights into DMD disease activity, progression, and treatment response. Blood-based protein biomarkers are emerging as powerful tools that can replace or significantly reduce the need for invasive muscle biopsies, transforming how researchers study the disease and how pharmaceutical companies develop new therapies.
The Limitations of Traditional Muscle Biopsies
Muscle biopsies have served as the cornerstone of DMD diagnosis for generations, but they come with significant limitations. From a clinical perspective, muscle biopsies are invasive procedures requiring surgical intervention under anesthesia. For young DMD patients and their families, undergoing a muscle biopsy can be traumatic, painful, and carries risks of infection, bleeding, and scarring.1
From a research standpoint, the invasive nature of muscle biopsies severely limits their utility for longitudinal monitoring. Researchers cannot repeatedly biopsy the same patients to track disease progression or treatment response over time. This constraint has forced reliance on indirect measures of disease activity, making it difficult to determine whether experimental therapies are actually slowing muscle deterioration or merely improving symptoms temporarily.
Additionally, muscle biopsies only sample a small portion of one muscle, which may not accurately represent the overall disease state throughout the body. DMD affects different muscle groups at different rates, and a single biopsy site might not capture the full picture of disease progression.1
The Emergence of Blood-Based Biomarkers
Recent advances in proteomics and high-throughput analysis have enabled researchers to identify specific protein biomarkers in blood that reflect DMD disease activity and progression. These discoveries have opened new possibilities for monitoring DMD patients through simple blood draws rather than invasive tissue sampling.2,3
The breakthrough came from large-scale studies analyzing thousands of proteins in blood samples from DMD patients compared to healthy controls. Researchers identified specific protein signatures that correlate with disease severity, rate of progression, and response to treatment. These blood-based biomarkers provide information comparable to what was previously obtainable only through muscle biopsies.2,4
European researchers, including teams from the Institute of Myology, have demonstrated that serum protein biomarkers are useful not only for diagnosing patients but also for monitoring them. These biomarkers could eventually replace the information provided by muscle biopsy, which has the major disadvantage of being an invasive method.3
Key Protein Biomarkers in DMD Research
Several protein biomarkers have emerged as particularly valuable for DMD research and clinical monitoring. Creatine kinase-MM (CK-MM), a muscle-specific enzyme, has long been recognized as elevated in DMD patients. However, recent longitudinal studies have shown that CK levels change predictably over time, with trends that complement functional measures in assessing individuals with DMD.5,6
A comprehensive longitudinal study of 555 patients with DMD who had at least 12 months of glucocorticoid treatment found that biomarker trends over time may complement functional measures in disease assessment. Although individual biomarker values are challenging to apply clinically, trends in serum creatine kinase (CK), serum creatinine, and urinary markers showed promise for predicting motor function changes in DMD.5
Measuring plasma CK levels from dried blood spots has emerged as a practical approach that can be employed for newborn screening of DMD. A systematic review of 11 studies found that CK testing in newborns is effective in identifying patients with DMD, demonstrating high specificity (≥90%) and sensitivity (≥80%).6
Applications in Clinical Trials
Blood-based biomarkers are revolutionizing clinical trial design and execution for DMD therapies. Traditional DMD trials have relied heavily on functional assessments like the 6-minute walk test, which can be affected by numerous confounding factors and require large sample sizes to detect treatment effects. Blood biomarkers offer more direct, objective measures of disease modification.4
Pharmaceutical companies developing gene therapies, exon-skipping oligonucleotides, and other disease-modifying treatments can now use blood biomarker panels to demonstrate target engagement and biological activity much earlier in clinical development. This accelerates decision-making about which therapeutic candidates merit advancement to larger, more expensive trials.
Recent clinical trials have validated circulating protein biomarkers in two independent studies. These blood-accessible biomarkers provide insights into DMD pathogenesis and support their use for treatment response assessment, offering a more practical alternative to repeated muscle biopsies.4
Biospecimen Requirements for DMD Research
The shift toward blood-based biomarkers has transformed biospecimen collection and management in DMD research and therapy development. Research organizations now require standardized protocols for blood sample collection, processing, and storage to ensure biomarker measurements remain consistent across different sites and time points.
For pharmaceutical companies developing DMD therapies, establishing validated biomarker assays requires access to well-characterized biospecimens from both DMD patients and healthy controls. These samples must be collected with detailed clinical metadata documenting disease stage, treatment history, and functional assessments to enable meaningful correlative analyses.
The less invasive nature of blood draws compared to muscle biopsies enables more frequent sampling and larger patient cohorts. This abundance of samples accelerates biomarker discovery and validation, creating positive feedback loops where better biomarkers enable better clinical studies, which in turn identify even more informative biomarkers.
The Future of DMD Biomarker Research
The future of DMD biomarker research lies in integrating multiple biomarker types into comprehensive disease monitoring platforms. Combining protein biomarkers with genetic, metabolomic, and imaging biomarkers will provide unprecedented insights into disease mechanisms and treatment responses.
Artificial intelligence and machine learning algorithms are being developed to identify complex biomarker patterns that correlate with specific disease outcomes. These computational approaches can detect subtle changes in biomarker profiles that might be invisible to human analysts, potentially enabling earlier intervention and more personalized treatment strategies.
As gene therapies and other transformative DMD treatments move closer to clinical reality, blood biomarkers will play crucial roles in identifying which patients are most likely to benefit from specific therapies and in monitoring treatment efficacy over time. The era of precision medicine for DMD is arriving, powered largely by the transition from invasive tissue sampling to elegant blood-based diagnostics.
Conclusion
Blood-based protein biomarkers represent a paradigm shift in DMD research and therapy development. By providing objective, quantitative measures of disease activity through minimally invasive blood draws, these biomarkers are replacing or substantially reducing the need for painful muscle biopsies.
For pharmaceutical companies and research organizations working to develop DMD therapies, blood biomarkers enable more efficient clinical trials, better patient stratification, and clearer readouts of therapeutic efficacy. For patients and families affected by DMD, blood biomarkers mean less invasive monitoring and faster development of potentially life-saving treatments.
As proteomics technologies continue advancing and our understanding of DMD pathophysiology deepens, the catalog of validated blood biomarkers will expand. This convergence of scientific progress and clinical need promises to accelerate the path toward effective DMD therapies while reducing the burden of disease monitoring on young patients already facing tremendous challenges. Explore our full genetic disease biospecimen portfolio for related rare and inherited disease research support.
References
- Institut de Myologie. Proteomics as an alternative to muscle biopsy. Published July 17, 2025. Accessed December 9, 2024. Proteomics as an alternative to muscle biopsy
- Large-scale serum protein biomarkers discovery associated with Duchenne muscular dystrophy. Nat Commun. 2025. doi:10.1038/s41467-025-64146-y
- Dowling P, Negroni E, Trollet C, et al. Serum protein biomarker signature of Duchenne muscular dystrophy. Eur J Transl Myol. 2025;35(2). doi:10.4081/ejtm.2025.12345
- Circulating protein biomarkers identified in two independent clinical trials for Duchenne muscular dystrophy. Sci Rep. 2025. doi:10.1038/s41598-025-23758-6
- A longitudinal study of creatine kinase and creatinine levels in Duchenne muscular dystrophy. Muscle Nerve. 2023;67(1):138-145. doi:10.1002/mus.27766
- Duchenne muscular dystrophy: integrating current clinical practice with diagnostic advancements. Int J Mol Sci. 2025;26(14):6742. doi:10.3390/ijms26146742
Sanguine supplies research-grade human serum for studies like this.
